Gender-Specific Health Research
There is a critical need for unbiased research examining gender-specific issues and diseases in order to improve health awareness, treatment outcomes, and access to quality, evidence-based healthcare.
The mission of the Foundation for Female Health Awareness includes the mandate to support new and existing research projects relevant to women’s pelvic health . We monitor and/or conduct industry-supported research regarding various drugs and devices specific to women’s pelvic health.
FFHA has the unique ability to play the important role of intermediary between industry and the researchers performing the study.
Academic Partners in FFHA Research Trials
FFHA Research Grants
FFHA is currently offering grants up to $10,000 for independent researchers that seek to study gender-specific pelvic health issues.
In order to further our mission of increasing gender-specific pelvic health education and awareness, we award research grants for projects focusing on women’s pelvic health.
See below for ongoing and completed research funded by the FFHA.
If you have questions about our grant application process, please email anoosha@femalehealthawareness.org.
Note: The FFHA is a registered 501(c)3 non-for-profit that supports unbiased research in women’s pelvic health. Funding received from the FFHA cannot be used to cover indirect costs charged by the study institution or any of the subsites.
Ongoing FDA Clinical Trials
DENARA: Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women: A Randomized Controlled Trial
SPONSOR: InMode MD Ltd.
The goal of this clinical trial is to learn if a vaginal radiofrequency (RF) device called MORPHEUSV works to treat overactive bladder (OAB) in women. Researchers also want to learn how safe the device is for this indication. This study will include women ages 22 to 80 who have had OAB symptoms for at least 6 months. The main questions it aims to answer are: Does the MORPHEUSV device lower the number of daily episodes of accidental urine leakage caused by urgency? Does it work better than a sham (placebo) treatment? Researchers will compare the MORPHEUSV device to a sham treatment to see how well it reduces symptoms of overactive bladder. Participants will: 1) Receive one session of either the MORPHEUSV or sham treatment. 2) Track their symptoms using a diary and questionnaires 3) Return for three to six follow-up visits over 12 months. This study is being conducted at multiple clinics in the United States.
ClinicalTrials.gov ID: NCT07209397
PARTICIPATING CENTERS:
- Stanford Medicine Department of Obstetrics & Gynecology; Palo Alto, California
- MedStar Health Research Institute; Washington D.C., District of Columbia
- Advanced Specialty Research; Boise, Idaho
- University of Chicago Medicine Urogynecology; Chicago, Illinois
- Cypress Medical Research Center; Wichita, Kansas
- Bay State Clinical Trials; Watertown, Massachusetts
- Urology Center, P.C.; Omaha, Nebraska
- UNLV Kirk Kerkorian School of Medicine Department of Gynecologic Surgery & Obstetrics; Las Vegas, Nevada
- Atrium Health Wake Forest Female Pelvic Health Division; Greensboro, North Carolina
APPROVE: A Randomized Controlled Trial Evaluating the Efficacy and Safety of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women
SPONSOR: Medstar Health Research Institute
The APPROVE trial is a multi-centered, randomized controlled trial designed to assess differences in symptom improvement, quality of life, bladder symptoms, satisfaction with treatment and continued treatment efficacy in women with overactive bladder (OAB) randomized to a prescription digital therapeutic (PDTx) app called RiSolve compared to standard behavioral education (handouts).
ClinicalTrials.gov ID: NCT06797245
PARTICIPATING CENTERS:
- University of Alabama at Birmingham; Birmingham, Alabama
- Stanford University; Palo Alto, California
- MedStar Health; Washington D.C., District of Columbia
- University of Chicago; Chicago, Illinois
- Curavit; Boston, Massachusetts
- Atrium Health Wake Forest Baptist; Winston-Salem, North Carolina
- Allegheny Health; Pittsburgh, Pennsylvania
- Medical University of South Carolina Health; Charleston, South Carolina
- UT Southwestern Medical Center; Dallas, Texas
- University of Wisconsin; Madison, Wisconsin
Current FFHA-Funded Research
Analysis of Costs, Risks and Benefits of Health Care for Pelvic Floor Disorders
PRINCIPAL INVESTIGATOR: Eric Sokol, MD; Stanford University School of Medicine, Palo Alto, CA.
Perceptions of Maternal Mortality in Missouri
PRINCIPAL INVESTIGATOR: Karen L. Florio, DO, MPH; Saint Luke’s Hospital of Kansas City, Kansas City, MO.
The goal of this qualitative analysis is to assess the knowledge and perceptions regarding maternal mortality (etiologies, people affected, where medical information is obtained, etc.) across generations in women living in Missouri. The hypothesis is that women in Missouri are not aware that maternal mortality is a problem in the state, nor do they understand the driver/etiologies/risk factors for maternal death. Researchers also hypothesize that women are not accessing medical information from reputable sources.
Randomized trial of Retropubic versus Single-incision Mid-Urethral Sling (Altis™) for Concomitant Management of Stress urinary incontinence during Native Tissue Vaginal Repair
PRINCIPAL INVESTIGATOR: Catherine Matthews, MD; Atrium Health Wake Forest Baptist Health, Winston-Salem, NC.
Trial to Assess the Efficacy of the CO2 Laser Therapy for the Treatment of Lichen Sclerosus
PRINCIPAL INVESTIGATOR: Mickey M. Karram, MD; Christ Hospital, Cincinnati OH.
Clinical Evaluation of Fractional Bi-Polar Radio-Frequency for Symptoms of Vulvovaginal Atrophy
PRINCIPAL INVESTIGATOR: Mickey M. Karram, MD; Christ Hospital, Cincinnati, OH.
The objective of this 12-month trial is to evaluate the safety and efficacy of the MorpheusV Applicator for Symptoms of Vulvovaginal Atrophy.
Pilot study to evaluate the use of a bipolar radio-frequency device in the treatment of Stress Urinary Incontinence (SUI) and Mixed Incontinence (SUI and Urge Incontinence)
PRINCIPAL INVESTIGATOR: Mickey M. Karram, MD; Christ Hospital, Cincinnati OH.
The purpose of this study is to conduct preliminary clinical safety and efficacy testing of a fractional radiofrequency device (RF SUI Treatment Device) for use in gynecology for the treatment of urinary incontinence, including stress urinary incontinence (SUI) the unintentional loss of urine due to activities like laughing, coughing, sneezing, lifting or exercise and mixed incontinence (SUI and urge incontinence). The primary objective is improvement from baseline to 3 months post treatment as documented in the Incontinence Quality of Life (IQOL) questionnaire. Secondary objectives are improvement from baseline to 3 months post treatment as documented by the following assessments: Voiding diary, Urosure test, MESA questionnaire, UDI-6 questionnaire, Investigator satisfaction and patient satisfaction PGI-I scale.
Transvaginal Radiofrequency Ablation with Morpheus ® for Treatment of Overactive Bladder: A Pilot Study
PRINCIPAL INVESTIGATOR: Mickey M. Karram, MD; Christ Hospital, Cincinnati OH.
Have a project idea that could advance women's health?
Apply for FFHA Grant Funding today!
Previous Research Funded by FFHA
Histological Study to Assess the CO2 Laser Therapy for the Treatment of Vaginal Atrophy
Principal Investigator: Mickey Karram. In preparation.
Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy for vaginal dryness/vaginal atrophy (VELVET Trial): The purpose of this multi-center clinical trial is to compare the efficacy and safety of CO2 fractional vaginal laser treatment to the current standard treatment, vaginal estrogen therapy, for the treatment of vulvovaginal atrophy (i.e. vaginal dryness and inflammation associated with menopause). This study is actively enrolling new study participants. Participating sites include the Cleveland Clinic, Cleveland OH, Washington Hospital Center, Washington DC, Christ Hospital, Cincinnati OH, Rhode Island Women’s and Infants Hospital, Providence, RI, Standford University, Standford CA, and Wake Forest Baptist Hospital, Winston Salem, NC.
Paraiso MFR, Ferrando CA, Sokol ER, Rardin CR, Matthews CA, Karram MM, Iglesia CB. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial. Menopause. 2020 Jan;27(1):50-56. doi: 10.1097/GME.0000000000001416. PMID: 31574047 Clinical Trial.
Vaginal and laparoscopic mesh hysteropexy for uterovaginal prolapse: a parallel cohort study (The VAULT Study): The purpose of this multi-center parallel cohort study was to compare the safety and efficacy of two surgical procedures for uterine prolapse: the laparoscopic sacral hysteropexy and the vaginal mesh hysteropexy. 153 women age 35-80 with uterine prolapse were enrolled from one of 8 clinical sites and received one of these two surgical procedures. Overall, both laparoscopic sacral hysteropexy and vaginal mesh hysteropexy resulted in similar outcomes 1 year after surgery with high rates of satisfaction. This study was awarded Best Surgical Paper at the 2015 annual meeting of the American Urogynecologic Society, Seattle, WA, Oct. 13-17, 2015.1.
Gutman RE, Rardin CR, Sokol ER, Matthews C, Park AJ, Iglesia CB, Geoffrion R, Sokol AI, Karram M, Cundiff GW, Blomquist JL, Barber MD.
Vaginal and laparoscopic mesh hysteropexy for uterovaginal prolapse: a parallel cohort study. Am J Obstet Gynecol. 2017 Jan;216(1):38.e1-38.e11. doi: 10.1016/j.ajog.2016.08.035. Epub 2016 Sep 3. PMID: 27596620.
A blinded multi-center randomized trial comparing TVT-SECUR “U” to the tension-free vaginal tape (TVT) for the surgical treatment of stress urinary incontinence (The SECURITY Trial): This multi-center clinical trial compared the retropubic midurethral sling (tension-free vaginal tape, TVT) to a single-incision mini-sling (TVT SECUR) for the treatment of female stress urinary incontinence. The mini-sling resulted in similar subjective cure rates to the TVT 1 year after surgery but in those women who were not cured, incontinence severity was greater after the mini-sling. This study was awarded the Best Clinical/Surgical Paper at the 2011 American Urogynecology Society Meeting and the 2011 International Urogynecologic Association Axel Ingelman-Sundberg Award for Best Abstract.
Evaluation and Management of Vaginal Mesh Complications: This grant supported a multi-center retrospective cohort study of 347 women presenting to a tertiary care urogynecology practice for evaluation and management of complications after vaginal mesh surgery for pelvic organ prolapse and stress urinary incontinence. Two hundred and sixty women in this study also completed a follow-up survey to evaluate their outcomes after medical or surgical management of their mesh complications. This grant resulted in the publication of two research papers:
Unger CA, Abbott S, Evans JM, Jallad K, Mishra K, Karram MM, Iglesia CB, Rardin CR, Barber MD. Outcomes following treatment for pelvic floor mesh complications. Int Urogynecol J. 2014 Jun;25(6):745-9. doi: 10.1007/s00192-013-2282-9. Epub 2013 Dec 7. PMID:24318564.
Abbott S, Unger CA, Evans JM, Jallad K, Mishra K, Karram MM, Iglesia CB, Rardin CR, Barber MD. Evaluation and management of complications from synthetic meshafter pelvic reconstructive surgery: a multicenter study. Am J Obstet Gynecol. 2014 Feb;210(2):163.e1-8. doi: 10.1016/j.ajog.2013.10.012. Epub 2013 Oct 11. PMID:24126300.
Transobturator tape compared with tension-free vaginal tape for the treatment of stress urinary incontinence: a randomized controlled trial: To compare the safety and efficacy of the transobturator tape to tension-free vaginal tape (TVT) in the treatment of stress urinary incontinence in patients with and without concurrent pelvic organ prolapse.
Barber MD, Kleeman S, Karram MM, Paraiso MF, Walters MD, Vasavada S, Ellerkmann M. Transobturator tape compared with tension-free vaginal tape for the treatment of stress urinary incontinence: a randomized controlled trial. Obstet Gynecol. 2008 Mar;111(3):611-21. doi: 10.1097/AOG.0b013e318162f22e. PMID: 18310363.
Medical Student Research Fellowship
FFHA provided a grant to support a year of research study for a student in the Cleveland Clinic Lerner College of Medicine of Case Western University graduating class of 2012. This grant supported Sara Abbott MD’s medical school clinical research thesis titled “A Model to Predict Failure of Uterine Artery Embolization.”In this project advanced statistical modeling were used to develop a nomogram that physicians can use to predict treatment failure and success for an individual patient considering uterine fibroid embolization for symptomatic fibroids. This project also served as her thesis for a Masters of Science in Clinical Research.
